The Base of COMBACTE's Future

Read more
General News Item

Smart, Innovative, Continuous: REMAP-CAP Launches First Video

The Adaptive Platform Trial for Community-Acquired Pneumonia, REMAP-CAP, launched its first of a series of videos. The video shows the uniqueness, smart and easy-to-handle design of REMAP-CAP.

REMAP-CAP's first of a series of videos

COMBACTE’s CLIN-Net is performing the site selection for REMAP-CAP and aims to select 250 hospitals across Europe.

As an adaptive platform, REMAP-CAP is designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment. Since the COVID-19 outbreak, the platform has extended its domains to investigate new treatments specifically for COVID-19 patients on the ICU and the ward. With the ability to improve the design according to new insights and already having the clinical trial infrastructure in place to implement these insights swiftly, various interventions can be tested simultaneously within multiple therapeutic domains.

Shortly after the intensification of the COVID-19 pandemic, five new COVID-19 domains that received ethical approval have been added in REMAP-CAP: Antiviral therapy, Immune Modulation therapy, Antibody therapy, Therapeutic anticoagulation and Vitamin C.

Benefits of REMAP-CAP

Coordinating investigator and intensivist Lennie Derde (UMC Utrecht): “We can test several groups of medicines at the same time. An adaptive platform trial is fairer for the participants. If a particular drug shows better results, a larger percentage of new patients will be allocated to that drug. Fewer people are exposed to less promising medicines. As a result, patients are more likely to benefit from the knowledge that is gradually yielded by the study. We also have faster results.”

Smart, Innovative, Continuous: REMAP-CAP Launches First Video 3

First Results

In a sub-study of the REMAP-CAP study, published in JAMA in September, it was shown that the use of corticosteroids increases the likelihood of survival of critically ill COVID-19 patients. The results confirm what a study from the University of Oxford previously showed: a third fewer deaths with dexamethasone treatment.

Follow, follow, follow

For the latest updates be sure to follow REMAP-CAP on Twitter, Linkedin, Instagram, Spotify and iTunes. Listen to the first episode of the REMAP-CAP Podcast!

Are you or your hospital interested in or want to join REMAP-CAP? Write to us!